hero-orange

Platform & Pipeline

Platform

Our platform consists of three fundamental elements:

Group-230-fix

14-3-3 Encyclopedia

The 14-3-3 encyclopedia provides a systematic understanding of the 14-3-3:client interface so that we can achieve predictive, efficient structure-chemotype pairing in a modular fashion, substantially streamlining the drug discovery process. With an extensive client database of binding motifs and 14-3-3:client protein structures, we can more quickly identify the most promising candidates from our library of privileged scaffolds to begin the screening process.

Pipeline

Our pipeline currently focuses on oncology, where multiple opportunities exist to engage currently undrugged targets that are involved in oncogenic signaling and gene expression, cell cycle dysregulation, and other cancer-driving processes. With five programs in early discovery, we expect to field at least one development candidate by 2H 2023.

PROGRAM
TARGET ACTIVITY
Stage
Competition
Program 1
Adaptor/Scaffold
Integrator / distributor of RTK & Oncogenic TK Signaling
Hit-To-Lead
Undrugged
Hit-To-Lead
Program 2
Transcription Factor
Effector of Multiple Oncogenic Signaling Pathways
Hit Exploration
Undrugged
Hit Exploration
Program 3
Phosphatase
Cell Cycle Regulator
Hit Exploration
Undrugged
Hit Exploration
Program 4
Regulatory Protein
Activator of Prevalent Oncogene
Hit-To-Lead
Early Clinical
Hit-To-Lead
Program 5
Transcription Factor
Effector of Oncogenic Signaling Pathway
Hit Finding
Early Clinical
Hit Finding